Background:  CDC2L1 is part of the Ser/Thr protein kinase family and CDC2/CDKX subfamily. CDC2L1 is involved in cell cycle progression, cytokinesis and apoptosis. Phosphorylation at Thr-448 or Tyr-449 inactivates the enzyme, while phosphorylation at Thr-595 activates it. There are several named isoforms that arise from alternative splicing. The p110 isoforms have been suggested to be involved in pre-mRNA splicing, potentially by phosphorylating the splicing protein SFRS7. The p58 isoform may act as a negative regulator of normal cell cycle progression. The cleaved p110 isoform, p110C, binds to the serine/threonine kinase PAK1, and to RANBP9. The p58 isoform but not the p110 isoforms or p110C interacts with CCND3. The p110 isoforms are found in large molecular weight complexes containing CCNL1 and SFRS7. CDC2L1 is expressed ubiquitously and there is some evidence of isoform-specific tissue distribution. The p58 isoform is specifically induced in G2/M phase of the cell cycle.

Description: Rabbit polyclonal to CDC2L1

Immunogen: KLH conjugated synthetic peptide derived from CDC2L1

Specificity:  ·Reacts with Human, Mouse, Rabbit, Cow, Pig, Dog and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 92 kDa;

·Immunohistochemistry (Frozen/paraffin tissue section): 1/100-500;

·Immunocytochemistry: 1/100-500;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.